ARS Pharmaceuticals Inc 2024年度报告

ARS Pharmaceuticals, Inc. Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☒No☐Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared orissued its audit report.☐ Ifsecurities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements.☐ Indicateby check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation receivedby any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of March 17, 2025 there were98,119,804shares of registrant’s common stock, $0.0001 par value per share, outstanding.The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $466.1million as ofJune 28, 2024 (the last trading day of the registrant’s most recently completed second quarter) based on the closing price of $8.51 as reported on theNasdaq Global Market on such date. Shares of the registrant’s common stock held by executive officers, directors, and their affiliates have been excludedfrom this calculation. This determination of affiliate status is not necessarily a conclusive determination for other purposes. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders, which the registrant intends to file pursuant toRegulation 14A with the Securities and Exchange Commission not later than April 30, 2025, are incorporated by reference into Part III of thisAnnual Report on Form 10-K. Table of Contents PART IItem 1.Business5Item1A.Risk Factors51Item1B.Unresolved Staff Comments102Item1C.Cybersecurity103Item 2.Properties104Item 3.Legal Proceedings104Item 4.Mine Safety Disclosures104 PARTIIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities105Item 6.[Reserved]106Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations106Item7A.Quantitative and Qualitative Disclosures About Market Risk119Item 8.Financial Statements and Supplementary Data120Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure150Item9A.Controls and Procedures150Item9B.Other Information151Item9C.Disclosure regarding Foreign Jurisdictions that Prevent Inspections151 PARTIIIItem 10.Directors, Executive Officers and Corporate Governance152Item 11.Executive Compensation152Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters152Item 13.Certain Relationships and Related Transactions, and Director Independence152Item 14.Principal Accountant Fees and Services152 PART IVItem 15.Exhibits, Financial Statement Schedules153Item 16.Form 10-K Summary155SIGNATURES PART I SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this “Annual Report”) contains forward-looking statements that involverisks and uncertainties. We make such forward-looking statements pursua